157 related articles for article (PubMed ID: 21304406)
1. Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.
Yoshimoto K; Kishida T; Nakano H; Matsui M; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Takeuchi M; Hisa Y; Mazda O
J Immunother; 2011 Mar; 34(2):139-48. PubMed ID: 21304406
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
4. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
5. [IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma].
Liu S; Lin Y; Tang S; Yang H; Liang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2001 Jun; 19(3):191-3. PubMed ID: 12539412
[TBL] [Abstract][Full Text] [Related]
6. Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma.
Liu S; Yang H; Liang C
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):323-6. PubMed ID: 12408755
[TBL] [Abstract][Full Text] [Related]
7. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity.
Matsui M; Kishida T; Nakano H; Yoshimoto K; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Yoshimoto T; Hisa Y; Mazda O
Cancer Res; 2009 Mar; 69(6):2523-30. PubMed ID: 19244121
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
10. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model.
Imagawa Y; Satake K; Kato Y; Tahara H; Tsukuda M
Auris Nasus Larynx; 2004 Sep; 31(3):239-45. PubMed ID: 15364358
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
13. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
14. [Combination radiation and gene therapy for head and neck squamous cell carcinoma in the murine model].
Liu SX; Yang H; Yuan YM; Guo YF; Tang ZQ; Liang CY
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 May; 39(5):278-82. PubMed ID: 15338865
[TBL] [Abstract][Full Text] [Related]
15. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
16. [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
Yang H; Liu S; Liang C; Peng W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):9-11, 30. PubMed ID: 15600166
[TBL] [Abstract][Full Text] [Related]
17. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
20. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]